Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular tonicity, nerve impulse transmission, cardiac contractility, and skeletal muscle function. Sodium chloride provides sodium and chloride ions to maintain extracellular fluid osmolarity and volume.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
20 mEq potassium chloride in 0.9% sodium chloride, intravenous infusion at a rate not exceeding 10-20 mEq/hour; maximum 150 mEq/day.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
The terminal elimination half-life of potassium is approximately 1-1.5 hours in individuals with normal renal function, reflecting rapid renal clearance. In renal impairment, half-life is significantly prolonged, necessitating dose adjustment.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Renal excretion accounts for approximately 90% of potassium elimination; the remaining 10% is eliminated via the gastrointestinal tract. Minor biliary/fecal loss is negligible in normal physiology.
Category C
Category A/B
Electrolyte
Electrolyte